Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Current Leases (2016 - 2025)

Lineage Cell Therapeutics (LCTX) has 12 years of Current Leases data on record, last reported at $43000.0 in Q3 2025.

  • For Q3 2025, Current Leases changed N/A year-over-year to $43000.0; the TTM value through Sep 2025 reached $43000.0, changed N/A, while the annual FY2024 figure was $1.1 million, 2009.62% up from the prior year.
  • Current Leases reached $43000.0 in Q3 2025 per LCTX's latest filing, down from $50000.0 in the prior quarter.
  • Across five years, Current Leases topped out at $1.1 million in Q4 2024 and bottomed at $17000.0 in Q2 2021.
  • Average Current Leases over 5 years is $328352.9, with a median of $52000.0 recorded in 2023.
  • Peak YoY movement for Current Leases: plummeted 98.63% in 2021, then skyrocketed 3117.24% in 2023.
  • A 5-year view of Current Leases shows it stood at $17000.0 in 2021, then skyrocketed by 111.76% to $36000.0 in 2022, then soared by 44.44% to $52000.0 in 2023, then soared by 2009.62% to $1.1 million in 2024, then plummeted by 96.08% to $43000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Current Leases were $43000.0 in Q3 2025, $50000.0 in Q2 2025, and $56000.0 in Q1 2025.